Novanta (NOVT) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Novanta (NOVT) do?
Novanta Inc (NOVT) is a U.S.-listed company in Technology (Scientific & Technical Instruments). What it does: Manufactures precision laser systems, optical scanners, and motion components for medical and industrial devices. Designs proprietary photonics, vision, and motion subsystems embedded directly into healthcare and industrial equipment. It is worth $4.34B on the market and sold $1.09B over the last year.
- Market cap
- $4.34B
- P/E ratio
- 87.3×
- Annual sales
- $1.09B
- Sector
- Technology
- Industry
- Scientific & Technical Instruments
- Brief updated
- Nov 07, 2026
Brands and businesses behind NOVT
- Riverpoint Medical: Manufactures specialized surgical fibers, bio-absorbable sutures, and custom medical textiles sold to device makers.
- Celera Motion: Produces precision optical encoders and direct drive motors for robotic surgery and industrial automation.
- Cambridge Technology: Sells galvanometer optical scanning heads and beam steering systems for laser medical procedures.
- WOM: Designs medical insufflators, fluid management pumps, and video cameras for minimally invasive laparoscopy.
- Synrad: Manufactures carbon dioxide pulsed laser tubes used in advanced materials processing and medical marking.
NOVT’s flags, in plain English
Each flag is a number from Novanta’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 07, 2026.
Low debt
Low debt, only 55% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 41.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 10.7% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Priced for Perfection
Priced at 87.3 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
1 more risk note open with the free trial. Try it free for 7 days.
Questions about NOVT
How big is Novanta?
Novanta’s market cap is $4.34B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.09B: what customers paid the company over the last year, before any costs.
What is NOVT’s P/E ratio?
NOVT’s P/E ratio is 87.3×. Investors pay about 87.3 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with NOVT?
Hospital capital spending cutbacks and elevated interest rates delay original equipment manufacturer purchasing cycles. That is one risk on Novanta’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Novanta’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. NOVT’s filings on SEC.gov. The Margin Monkey is research, not advice.
